← Approve Suite Weekly

Approve Suite Weekly · Tuesday, November 10, 2026 · read online

8-K: Aldeyra Therapeutics, Inc. mentions complete response letter

Aldeyra receives complete response letter for ADX-2191 in primary vitreoretinal lymphoma. The CRL cites lack of substantial evidence of effectiveness and rejection of the planned SPA protocol. This denies approval for ADX-2191 and may delay or prevent resubmission, potentially affecting FDA interactions on Aldeyra's other programs including reproxalap.

Abiomed voluntarily recalls Impella Optical Controller worldwide for hardware, firmware, and software defects. Class I recall of a critical cardiac device control interface due to multiple failures affecting operator control, pump operation, and clinical data accuracy. Defects range from cassette recognition failure to potential loss of console control and incorrect hemodynamic calculations during use.

The pattern? Recalls led the week with 77, ahead of 8-K filings (76), out of 188 counted.

This week's author: Ryan Burke, Approve Suite

Read time: 5 min

Top stories

  1. 8-K: Aldeyra Therapeutics, Inc. mentions complete response letter
  2. Class I: Abiomed, Inc. — Impella Optical Controller, Packaged. Primary user control interface for the Impella Catheter, a catheter-based heart pump.
  3. NCT06374368: Small Bowel Diversion — Now TERMINATED

Signals

  1. 8-K: REGENXBIO Inc. mentions clinical hold
  2. 8-K: Lantheus Holdings, Inc. mentions complete response letter
  3. Class I: Abiomed, Inc. — Automated Impella Controller, Packaged. Primary user control interface for the Impella Catheter, catheter-based heart pump.
  4. Class I: Abiomed, Inc. — Impella Connect Optical AIC, Packaged. Primary user control interface for the Impella Catheter, a catheter-based heart pump.
  5. NCT04273048: The MOM TO BE Study — Now TERMINATED
  6. Medical Devices; Ear, Nose, and Throat Devices; Classification of the External Mechanical Stimulator for the Relief of Congestion

8-K: Aldeyra Therapeutics, Inc. mentions complete response letter

8-K · Aldeyra Therapeutics, Inc.

Aldeyra receives complete response letter for ADX-2191 in primary vitreoretinal lymphoma.

Why it matters. The CRL cites lack of substantial evidence of effectiveness and rejection of the planned SPA protocol. This denies approval for ADX-2191 and may delay or prevent resubmission, potentially affecting FDA interactions on Aldeyra's other programs including reproxalap.

What to watch. Items 1.01, 2.02 and 8.01 carry the material terms; the exhibits hold the detail.

READ MORE → · open in Approve Suite

Presented by Approve Suite

Put a watchlist on this. Name your CDMO and competitors; get these the day they post. $79/mo, no card to start. See pricing →

Class I: Abiomed, Inc. — Impella Optical Controller, Packaged. Primary user control interface for the Impella Catheter, a catheter-based heart pump.

Class I · Abiomed Inc.

Abiomed voluntarily recalls Impella Optical Controller worldwide for hardware, firmware, and software defects.

Why it matters. Class I recall of a critical cardiac device control interface due to multiple failures affecting operator control, pump operation, and clinical data accuracy. Defects range from cassette recognition failure to potential loss of console control and incorrect hemodynamic calculations during use.

What to watch. The classification and, later, the termination notice both post to openFDA; Class I recalls also appear as safety alerts.

READ MORE → · open in Approve Suite

Presented by Approve Suite

Put a watchlist on this. Name your CDMO and competitors; get these the day they post. $79/mo, no card to start. See pricing →

NCT06374368: Small Bowel Diversion — Now TERMINATED

Institute for Clinical and Experimental Medicine

NCT06374368 small bowel diversion trial terminated for safety due to serious complications.

Why it matters. Trial halt signals that jejuno-colic diversion poses unacceptable safety risks including hepatic fibrosis and metabolic complications. This finding impacts the clinical development pathway for bowel anastomosis procedures in metabolic disease.

What to watch. A stopped or suspended trial is often followed within days by an 8-K or a press release from the sponsor.

READ MORE → · open in Approve Suite

By the numbers

Inspections: 0 NAI · 0 VAI · 0 OAI

Warning letters: 0

Class I recalls: 12 (Class II 62, Class III 3)

Trial stops and status changes: 17 (results posted: 5)

Raises: 8, $563M disclosed

294 events, down 51% on the prior 7 days.

205 listed companies report under 12 months of runway.

Signals

1. 8-K: REGENXBIO Inc. mentions clinical hold 8-K · REGENXBIO Inc. app

2. 8-K: Lantheus Holdings, Inc. mentions complete response letter 8-K · Lantheus Holdings, Inc. app

3. Class I: Abiomed, Inc. — Automated Impella Controller, Packaged. Primary user control interface for the Impella Catheter, catheter-based heart pump. Class I · Abiomed Inc. app

4. Class I: Abiomed, Inc. — Impella Connect Optical AIC, Packaged. Primary user control interface for the Impella Catheter, a catheter-based heart pump. Class I · Abiomed Inc. app

5. NCT04273048: The MOM TO BE Study — Now TERMINATED Arkansas Children's Hospital Research Institute app

6. Medical Devices; Ear, Nose, and Throat Devices; Classification of the External Mechanical Stimulator for the Relief of Congestion Final rule app

Why this exists

Approve Suite Weekly exists so a QA or RA lead can read one email on Tuesday and know what changed in FDA regulation, inspections and trials in the past week. Every line links to its public source.

Sponsor this email

How was this week's email?

AwesomeDecentNot great

Informational only. Not regulatory, legal, or medical advice. Every item links to its public source.
Approve Suite · Unsubscribe · Archive
Catalyst Collective, LLC, c/o Legalinc Corporate Services Inc., 131 Continental Dr, Suite 305, Newark, DE 19713